12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revlimid lenalidomide regulatory update

Celgene withdrew a European application to extend the label of multiple myeloma (MM) drug Revlimid lenalidomide to include maintenance treatment in newly diagnosed MM patients who have not progressed following initial treatment, or as maintenance therapy following autologous stem cell transplantation. According to Celgene, EMA's...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >